Intriguingly, emerging evidence suggests that SGLT2 inhibitors may also indirectly bolster cardiac resilience by upregulating ALDH2 expression [73], which could provide a dual therapeutic benefit—especially for individuals carrying the ALDH2*2 mutation associated with DCM. The gene discussed is SLC5A2; the disease is familial dilated cardiomyopathy.